Free Trial
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel Free SXTP Stock Alerts

60 Degrees Pharmaceuticals (SXTP) Competitors

60 Degrees Pharmaceuticals logo
$1.36 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$1.32 -0.04 (-3.01%)
As of 06/12/2026 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SXTP vs. ZIVO, LEXX, ANEB, INAB, and JSPR

Should you buy 60 Degrees Pharmaceuticals stock or one of its competitors? MarketBeat compares 60 Degrees Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 60 Degrees Pharmaceuticals include ZIVO Bioscience (ZIVO), Lexaria Bioscience (LEXX), Anebulo Pharmaceuticals (ANEB), IN8bio (INAB), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry.

How does 60 Degrees Pharmaceuticals compare to ZIVO Bioscience?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, indicating a potential upside of 918.38%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than ZIVO Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ZIVO Bioscience has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-574.91% N/A -131.48%
ZIVO Bioscience N/A N/A -2,240.92%

60 Degrees Pharmaceuticals has a beta of 2.65, indicating that its share price is 165% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market.

60 Degrees Pharmaceuticals has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.41M2.57-$7.36M-$8.92N/A
ZIVO Bioscience$15.85K961.38-$7.78M-$1.71N/A

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for ZIVO Bioscience. 60 Degrees Pharmaceuticals' average media sentiment score of 0.94 beat ZIVO Bioscience's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Positive
ZIVO Bioscience Neutral

Summary

60 Degrees Pharmaceuticals beats ZIVO Bioscience on 10 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Lexaria Bioscience?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lexaria Bioscience has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-574.91% N/A -131.48%
Lexaria Bioscience N/A -206.02%-162.53%

60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, indicating a potential upside of 918.38%. Lexaria Bioscience has a consensus target price of $1.50, indicating a potential upside of 144.10%. Given 60 Degrees Pharmaceuticals' higher possible upside, equities analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Lexaria Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lexaria Bioscience
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

60 Degrees Pharmaceuticals has higher revenue and earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.41M2.57-$7.36M-$8.92N/A
Lexaria Bioscience$710K21.46-$11.90M-$0.47N/A

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Lexaria Bioscience. 60 Degrees Pharmaceuticals' average media sentiment score of 0.94 beat Lexaria Bioscience's score of 0.62 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Positive
Lexaria Bioscience Positive

60 Degrees Pharmaceuticals has a beta of 2.65, suggesting that its share price is 165% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Summary

60 Degrees Pharmaceuticals beats Lexaria Bioscience on 9 of the 14 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Anebulo Pharmaceuticals has a beta of -1.88, meaning that its share price is 288% less volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.65, meaning that its share price is 165% more volatile than the broader market.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Anebulo Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 0.94 beat Anebulo Pharmaceuticals' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anebulo Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
60 Degrees Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 918.38%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Anebulo Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anebulo Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

60 Degrees Pharmaceuticals has higher revenue and earnings than Anebulo Pharmaceuticals. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anebulo PharmaceuticalsN/AN/A-$8.48M-$0.19N/A
60 Degrees Pharmaceuticals$1.41M2.57-$7.36M-$8.92N/A

Anebulo Pharmaceuticals has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Anebulo PharmaceuticalsN/A -74.57% -68.96%
60 Degrees Pharmaceuticals -574.91%N/A -131.48%

Summary

60 Degrees Pharmaceuticals beats Anebulo Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to IN8bio?

IN8bio (NASDAQ:INAB) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

IN8bio has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.65, meaning that its share price is 165% more volatile than the broader market.

IN8bio currently has a consensus target price of $4.00, indicating a potential upside of 179.72%. 60 Degrees Pharmaceuticals has a consensus target price of $13.85, indicating a potential upside of 918.38%. Given 60 Degrees Pharmaceuticals' higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than IN8bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IN8bio
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, IN8bio and IN8bio both had 2 articles in the media. IN8bio's average media sentiment score of 1.43 beat 60 Degrees Pharmaceuticals' score of 0.94 indicating that IN8bio is being referred to more favorably in the media.

Company Overall Sentiment
IN8bio Positive
60 Degrees Pharmaceuticals Positive

60 Degrees Pharmaceuticals has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IN8bioN/AN/A-$19.44M-$2.61N/A
60 Degrees Pharmaceuticals$1.41M2.57-$7.36M-$8.92N/A

92.1% of IN8bio shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 14.5% of IN8bio shares are held by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

IN8bio has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat IN8bio's return on equity.

Company Net Margins Return on Equity Return on Assets
IN8bioN/A -96.39% -80.18%
60 Degrees Pharmaceuticals -574.91%N/A -131.48%

Summary

IN8bio and 60 Degrees Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Jasper Therapeutics?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

In the previous week, 60 Degrees Pharmaceuticals and 60 Degrees Pharmaceuticals both had 2 articles in the media. 60 Degrees Pharmaceuticals' average media sentiment score of 0.94 equaled Jasper Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
60 Degrees Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Jasper Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, indicating a potential upside of 918.38%. Jasper Therapeutics has a consensus price target of $13.14, indicating a potential upside of 2,772.13%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than 60 Degrees Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Jasper Therapeutics
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33

60 Degrees Pharmaceuticals has a beta of 2.65, meaning that its share price is 165% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3, meaning that its share price is 200% more volatile than the broader market.

Jasper Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-574.91% N/A -131.48%
Jasper Therapeutics N/A -613.51%-162.52%

60 Degrees Pharmaceuticals has higher revenue and earnings than Jasper Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.41M2.57-$7.36M-$8.92N/A
Jasper TherapeuticsN/AN/A-$75.80M-$3.23N/A

Summary

Jasper Therapeutics beats 60 Degrees Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Get 60 Degrees Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SXTP vs. The Competition

Export
Metric60 Degrees PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.62M$2.99B$6.52B$12.05B
Dividend YieldN/A1.76%2.67%5.66%
P/E Ratio-0.1518.8424.0024.42
Price / Sales2.57326.45515.84118.72
Price / CashN/A55.8827.4837.92
Price / Book-0.233.9810.606.82
Net Income-$7.36M$75.79M$3.57B$337.56M
7 Day Performance-4.90%1.57%0.59%1.16%
1 Month Performance-2.16%-0.73%1.54%3.16%
1 Year Performance-84.62%23.44%25.41%30.60%

60 Degrees Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SXTP
60 Degrees Pharmaceuticals
3.2056 of 5 stars		$1.36
flat		$13.85
+918.4%		-84.6%$3.62M$1.41MN/A3
ZIVO
ZIVO Bioscience
N/A$3.72
-15.6%		N/A-73.8%$15.43M$15.85KN/A10
LEXX
Lexaria Bioscience
2.2579 of 5 stars		$0.62
+3.3%		$1.50
+141.5%		-37.1%$15.40M$710KN/A7
ANEB
Anebulo Pharmaceuticals
0.0294 of 5 stars		$0.38
-6.4%		N/A-65.8%$15.30MN/AN/A4
INAB
IN8bio
4.0958 of 5 stars		$1.54
-1.3%		$4.00
+159.7%		-36.7%$15.16MN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SXTP) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel